| ID | 1015 |
| Name of the vaccine | Kinrix |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 4 to 6 years |
| Description of the vaccine | Diphtheria, tetanus toxoids, acellular pertussis adsorbed and inactivated poliovirus vaccine. |
| Name of the manufacturer | GlaxoSmithKline Biologicals and GSK Vaccines GmbH |
| Name of the manufacturing country | Belgium and Germany |
| Year of manufacture | 2008 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | Assessed by comparing antibody levels one month after vaccination with known serological correlates of protection for these diseases. |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose(0.5 mL) |
| Mechanism of action | Serum diphtheria antitoxin level of 0.1 IU/mL is protective. |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series. |
| Export | Distributed by GlaxoSmithKline |
| Approval | US FDA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For acellular pertussis, tetanus and poliovirus. |
| Side effects of vaccine | Injection site pain, redness, increase in arm circumference, swelling, drowsiness, fever and loss of appetite. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 18980534 |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/80128/download |
| Other name | NA |
| Additional Links | NA
|